You’ve most likely had an infection that required treatment with antibiotics. At the time that you were prescribed antibiotics, you probably heard that familiar spiel about needing to take the entire course of antibiotics even if you feel better before finishing them. You might be wondering, why does it matter? Hopefully after reading this post you will be able to answer that question for yourself.
As you might imagine, bacteria developing the ability to survive antibiotic treatment is bad news for us. This means that over time, our commonly used antibiotics are becoming less effective at killing bacteria. As bacteria evolves more antibiotic resistance, we may no longer be able to treat common infections unless we come up with another alternative treatment. It is important that we try to delay the evolution of antibiotic resistance as much as we can to buy time to develop other effective treatments. So what are the driving forces of bacterial evolution and what can we do about it?
Continue reading “Finish your antibiotics completely, the future depends on it!”
The microbiome of the gut specifically plays a role in chronic metabolic disease, one of which is Chronic Kidney Disease (CKD) (Ren et al. 2020) which this blog post specifically covers. CKD is a chronic condition because the damage to kidneys occurs over a long time period, inhibiting their ability to filter blood and toxins. As the damage occurs over time there is increasing risk that patients will end up on dialysis or need transplantation. The sooner CKD can be diagnosed the higher chance a patient has to protect their kidneys (“What is chronic Kidney disease?” 2017). CKD is an important disease to discuss since approximately 13.4% of the global population suffers from it and around 30 million people in the U.S. (Ren et al. 2020). Sufferers have a greatly increased risk of morbidity and mortality, as well as suffering from the significant healthcare costs that arise with this disease. For most patients CKD is not diagnosed until it is in a very progressed stage because the clinical symptoms are normally nonexistent in the early stages, meaning that most end up in end-stage renal failure (ESRF) which requires dialysis, transplantation, or other costly and long-term medical procedures. In 2012, Viziri et al. demonstrated the relationship between the gut microbiome and CKD. Gut derived uremic toxins, created by enzymes that the microbiota of the gut harbor are a factor in the progression of CKD and in previous studies it has been observed that as renal function decreases there is an increase in these toxins. Even though we know the connections with advanced stages of the disease, there is little research that has been done to potentially use the microbiome to diagnose early stage CKD, which leads to the researchers main question. Continue reading “Could the Gut Microbiome be the Answer to Chronic Kidney Disease?”
In the 1940s Sir Alexander Fleming released the antibiotic Penicillin to the public transforming modern medicine forever. The emergence of antibiotics has had a profound impact on our lives, helping to increase our average life span from 56 to nearly 80 years (Ventola 2015). Antibiotics are an effective tool in fighting infection and have greatly reduced surgical complications. However, the flurry of excitement around these wonder drugs quickly went away. It was realized that the very microbes these drugs were supposed to be fighting were actually making them stronger and eventually became resistant to them. Continue reading “The Selflessness of Bacteria is Making Our Drugs Less Effective”
“Dad, you have to try it, don’t you?’ Mary insists again.
Enrique doesn’t answer his daughter. What she’s implying will make him spend even more time in the hospital, to help someone in the distant future whom he will never meet, maybe. When he was 70, Enrique was diagnosed with acute myeloid leukemia (AML). As he understands it, some of his blood cells will never mature and perform the correct functions in his body. This cancer can be cured through chemotherapy in 25% of cases, but in most cases cannot be treated or reversed (Kornblau 2014). Enrique is contemplating joining a drug trial. In any given trial there is only a 10% chance that a patient will respond to the specific drug tested (Kornblau 2014). Some therapeutic drugs work for some patients, but how to match a patient to a drug is unknown; this is what the study Enrique might join is trying to figure out. Continue reading “The Chronicles of Evolutionary Weight in the Fight Against Cancer”